In order to further reveal the relevant biological mechanism, RNA-seq, and ACRIP-Seq were performed to identify HSP90AA1 as an intermediate molecular target for promoting drug resistance in ERS HCC during NAT10-mediated acetylation. The gene discussed is NAT10; the disease is hepatocellular carcinoma.